国药现代：全资子公司取得药品注册证书

Core Viewpoint - China National Pharmaceutical Modern (国药现代) has received approval from the National Medical Products Administration for the registration of Fumaric Acid Quetiapine Sustained-Release Tablets, which may enhance its product portfolio and market position [1] Group 1: Company Overview - China National Pharmaceutical Modern's subsidiary, Shanghai Modern Pharmaceutical Co., Ltd., has been granted a drug registration certificate for Fumaric Acid Quetiapine Sustained-Release Tablets [1] - As of the latest report, the company's market capitalization stands at 13.7 billion yuan [1] Group 2: Revenue Composition - For the year 2024, the revenue composition of China National Pharmaceutical Modern is as follows: - Formulations account for 49.84% - Intermediates and raw materials account for 47.53% - Other businesses account for 2.44% - Health-related products account for 0.19% [1]